LivaNova (NASDAQ:LIVN – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a research note issued to investors on Thursday, Benzinga reports. They presently have a $75.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 46.68% from the stock’s current price.
A number of other brokerages have also recently commented on LIVN. The Goldman Sachs Group began coverage on shares of LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price for the company. Stifel Nicolaus upped their target price on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Robert W. Baird upped their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $69.17.
Get Our Latest Analysis on LivaNova
LivaNova Stock Performance
LivaNova (NASDAQ:LIVN – Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.15. LivaNova had a net margin of 1.91% and a return on equity of 13.81%. The company had revenue of $318.60 million during the quarter, compared to the consensus estimate of $305.05 million. As a group, analysts expect that LivaNova will post 2.58 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Hexagon Capital Partners LLC increased its holdings in LivaNova by 117.8% in the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after buying an additional 370 shares in the last quarter. Fifth Third Bancorp increased its holdings in LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after buying an additional 332 shares in the last quarter. Lazard Asset Management LLC purchased a new position in LivaNova in the first quarter valued at about $84,000. Canada Pension Plan Investment Board purchased a new position in LivaNova in the second quarter valued at about $88,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of LivaNova in the first quarter valued at approximately $94,000. 97.64% of the stock is owned by hedge funds and other institutional investors.
About LivaNova
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
See Also
- Five stocks we like better than LivaNova
- Top Stocks Investing in 5G Technology
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- 3 Small Caps With Big Return Potential
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- What is a buyback in stocks? A comprehensive guide for investors
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.